Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse

Journal of Immunology

Volumn 175, Issue 6, 2005, Pages 3663-3673

  Singh, Reshma ^a   Dominiecki, Mary E ^a,c   Jaffee, Elizabeth M ^b   Paterson, Yvonne ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SLIPPERY ROCK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; LISTERIA MONOCYTOGENES LISTERIOLYSIN O E7 FUSION PROTEIN; LISTERIA MONOCYTOGENES LISTERIOLYSIN O EXTRACELLULAR DOMAIN 1 FUSION PROTEIN; LISTERIA MONOCYTOGENES LISTERIOLYSIN O EXTRACELLULAR DOMAIN 2 FUSION PROTEIN; LISTERIA MONOCYTOGENES LISTERIOLYSIN O EXTRACELLULAR DOMAIN 3 FUSION PROTEIN; LISTERIA MONOCYTOGENES LISTERIOLYSIN O INTRACELLULAR DOMAIN 1 FUSION PROTEIN; LISTERIA MONOCYTOGENES LISTERIOLYSIN O INTRACELLULAR DOMAIN 2 FUSION PROTEIN; LISTERIOLYSIN; LISTERIOLYSIN O; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER MODEL; CELL STRAIN 3T3; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNOGENICITY; LISTERIA MONOCYTOGENES; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN SECRETION; T LYMPHOCYTE; TUMOR CELL LINE; VACCINATION;

EID: 24744433094     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.6.3663     Document Type: Article

References (51)

1. Bargmann, C. I., M. C. Hung, and R. A. Weinberg. 1986. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319: 226-230.
2. Kim, H., and W. J. Muller. 1999. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp. Cell Res. 253: 78-87.
3. King, C. R., M. H. Kraus, and S. A. Aaronson. 1985. Amplification of a novel v-erB-related gene in human mammary carcinoma. Science 229: 974-976.
4. Yarden, Y., and M. X. Sliwkowski. 2001. Untangling the ErbB signaling network. Nat. Rev. Mol. Cell Biol. 2: 127-137.
5. Disis, M. L., and M. A. Cheever. 1997. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv. Cancer Res. 71: 343-371.
6. Knutson, K. L., K. Schiffman, K. Rinn, and M. L. Disis. 1999. Immunotherapeutic approaches for the treatment of breast cancer. J. Mammary Gland Biol. Neoplasia 4: 353-365.
7. Li, B. D., S. P. Harlow, R. M. Budnick, D. L. Sheedy, and C. C. Stewart. 1994. Detection of HER-2/neu oncogene amplification in flow cytometry-sorted breast ductal cells by competitive polymerase chain reaction. Cancer 73: 2771-2778.
8. Cohen, B. D., C. B. Siegall, S. Bacus, L. Foy, J. M. Green, I. Hellstrom, K. E. Hellstrom, and H. P. Fell. 1998. Role of epidermal growth factor receptor family members in growth and differentiation of breast carcinoma. Biochem. Soc. Symp. 63: 199-210.
9. Coronella, J. A., P. Telleman, G. A. Kingsbury, T. D. Truoung, S. Hays, and R. P. Junghans. 2001. Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res. 61: 7889-7899.
10. Peoples, G. E., R. C. Smith, D. C. Linehan, I. Yoshino, P. S. Goedegeburre, and T. J. Eberlein. 1995. Shared T cell epitopes in epithelial tumors. Cell. Immunol. 164: 279-286.
11. Tuttle, T. M., B. W. Anderson, W. E. Thompson, J. E. Lee, A. Sahin, T. L. Smith, K. H. Grabstein, J. T. Wharton, C. G. Ioannides, and J. L. Murray. 1998. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. Clin. Cancer Res. 4: 2015-2024.
12. Southwick, F. S., and D. L. Purich. 1996. Intracellular pathogenesis of listeriosis. N. Engl. J. Med. 334: 770-776.
13. Dussurget, O., J. Pizarro-Cerda, and P. Cossart. 2004. Molecular determinants of Listeria monocytogenes virulence. Ann. Rev. Microbiol. 58: 587-610.
14. Mackaness, G. B. 1962. Cellular resistance to infection. J. Exp. Med. 116: 381-406.
15. Gedde, M. M., D. E. Higgins, L. G. Tilney, and D. A. Portnoy. 2000. Role of listeriolysin O in cell-to-cell spread of Listeria monocytogenes. Infect. Immun. 68: 999-1003.
16. + T cells through IL-12 produced by Listeria-induced macrophages. Science 260: 547-549.
17. Ikonomidis, G., Y. Paterson, F. J. Kos, and D. A. Portnoy. 1994. Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes. J. Exp. Med. 180: 2209-2218.
18. Paterson, Y., and R. S. Johnson. 2004. Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens. Expert Rev. Vac. 3(4 Suppl.): S119-S134.
19. Gunn, G. R., A. Zubair, C. Peters, Z. K. Pan, T. C. Wu, and Y. Paterson. 2001. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J. Immunol. 167: 6471-6479.
20. Pan, Z. K., L. M. Weiskirch, and Y. Paterson. 1999. Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res. 59: 5264-5269.
21. Pan, Z. K., G. Ikonomidis, A. Lazenby, D. Pardoll, and Y. Paterson. 1995. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat. Med. 1: 471-477.
22. Machiels, J. P. H., R. T. Reilly, L. A. Emens, A. M. Ercolini, R. Y. Lei, D. Weintraub, F. I. Okoye, and E. M. Jaffee. 2001. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61: 3689-3697.
23. + T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J. Immunol. 171: 2161-2169.
24. Manjili, M. H., X. Y. Wang, X. Chen, T. Martin, E. A. Repasky, R. Henderson, and J. R. Subjeck. 2003. HSP110-HER-2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J. Immunol. 171: 4054-4061.
25. Reilly, R. T., J. P. H. Machiels, L. A. Emens, A. M. Ercolini, R. I. Okoye, R. Y. Lei, D. Weintraub, and E. M. Jaffee. 2001. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res. 61: 880-883.
26. Ercolini, A. M., J. P. Machiels, Y. C. Chen, J. E. Slansky, M. Giedlen, R. T. Reilly, and E. M. Jaffee. 2003. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J. Immunol. 170: 4273-4280.
27. Reilly, R. T., M. B. C. Gottlieb, A. M. Ercolini, J. P. H. Machiels, C. E. Kane, F. I. Okoye, W. J. Muller, K. H. Dixon, and E. M. Jaffee. 2000. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 60: 3569-3576.
28. Weiskirch, L. M., Z. K. Pan, and Y. Paterson. 2001. The tumor recall response of antitumor immunity primed by a live, recombinant Listeria monocytogenes vaccine comprises multiple effector mechanisms. Clin. Immunol. 98: 346-357.
29. + T lymphocyte responses. Eur. J. Immunol. 34: 1011-1020.
30. Guy, C. T., M. A. Webster, M. Schaller, T. J. Parsons, R. D. Cardiff, and W. J. Muller. 1992. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 89: 10578-10582.
31. Sewell, D. A., V. Shahabi, G. R. Gunn 3rd, Z. K. Pan, M. E. Dominiecki, and Paterson Y. 2004. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res. 64: 8821-8825.
32. Decatur, A. L., and D. A. Portnoy. 2000. A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science 290: 992-995.
33. Peng, X., S. F. Hussain, and Y. Paterson. 2004. The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function. J. Immunol. 172: 6030-6038.
34. Gallucci, S., and P. Matzinger. 2001. Danger signals: SOS to the immune system. Cur. Opin. Immunol. 13: 114-119.
35. Chen, Y., D. Hu, D. J. Eling, J. Robbins, and T. J. Kipps. 1998. DNA vaccines encoding full-length or truncated neu induce protective immunity against neu-expressing mammary tumors. Cancer Res. 58: 1965-1971.
36. Chang, S. Y., K. C. Lee, S. Y. Ko, H. J. Ko, and C. Y. Kang. 2004. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. Int. J. Cancer 111: 86-95.
37. Rovero, S., A. Amici, E. Di Carlo, R. Bei, P. Nanni, E. Quagliano, P. Porcedda, K. Boggio, A. Smorlesi, P. L. Lollini, et al. 2000. DNA vaccination against rat Her-2/neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 165: 5133-5142.
38. Lin, C. C., C. W. Chou, A. L. Shiau, C. F. Tu, T. M. Ko, Y. L. Chen, B. C. Yang, M. H. Tao, and M. D. Lai. 2004. Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu. Mol. Ther. 10: 290-301.
39. Ahmad, M., R. C. Rees, and S. A. Ali. 2004. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol. Immunother. 53: 844-854.
40. Knutson, K. L., B. Almand, Y. Dang, and M. L. Disis. 2004. neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res. 64: 1146-1151.
41. Duraiswamy, J., M. Bhardwaj, J. Tellam, G. Connolly, L. Cooper, D. Moss, S. Thomson, P. Yotnda, and R. Khanna. 2004. Induction of therapeutic T cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine. Cancer Res. 64: 1483-1489.
42. Disis, M. L., V. Goodell, K. Schiffman, and K. L. Knutson. 2004. Humoral epitope-spreading following immunizations with a HER-2/neu peptide based vaccine in cancer patients. J. Clin. Immunol. 24: 571-578.
43. van der Most, R. G., K. Murali-Krishna, J. G. Lanier, E. J. Wherry, M. T. Puglielli, J. N. Blattman, A. Sette, and R. Ahmed. 2003. Changing immu-nodominance patterns in antiviral CD8 T cell responses after loss of epitope presentation or chronic antigenic stimulation. Virology 315: 93-102.
44. Stumbles, P. A., R. Himbeck, J. A. Frelinger, E. J. Collins, R. A. Lake, and B. W. S. Robinson. 2004. Cutting edge: Tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J. Immunol. 173: 5923-5928.
45. Nowak, A. K., R. A. Lake, A. L. Marzo, B. Scott, W. R. Heath, E. J. Collins, J. A. Frelinger, and B. W. S. Robinson. 2003. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J. Immunol. 170: 4905-4913.
46. + T cells in tumor-bearing mice. J. Immunol. 174: 2563-2572.
47. + T cell repertoire against HER-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur. J. Immunol. 34: 752-761.
48. + T cells during negative selection results in an altered antiviral T cell hierarchy. J. Immunol. 170: 1231-1239.
49. Makki, A., G. Weidt, N. E. Blachere, L. Lefrancois, and P. K. Srivastava. 2002. Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor. Cancer Immun. 2: 4-12.
50. Kedl, R. M., J. W. Kappler, and P. Marrack. 2003. Epitope dominance, competition and T cell affinity maturation. Curr. Opin. Immunol. 15: 120-127.
51. Gallo, P., S. Dharmapuri, M. Nuzzo, D. Maldini, M. Iezzi, F. Cavallo, P. Musiani, G. Forni, and P. Monaci. 2005. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int. J. Cancer 113: 67-77.